SCHEMBL30509999

SCHEMBL30509999

c1ccc(-c2cccc(-c3ccn(Cc4cccnc4)n3)c2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
KDM4E B2RXH2 2/20 0.48
NPC1 O15118 2/20 0.48
LMNA P02545 2/20 0.48
HPGD P15428 2/20 0.48
RAB9A P51151 2/20 0.48
NFKB1 P19838 1/20 0.48
NFKB2 Q00653 1/20 0.48
RELA Q04206 1/20 0.48
L3MBTL1 Q9Y468 2/20 0.46
TEK Q02763 4/20 0.44
KDR P35968 3/20 0.44
CYP2E1 P05181 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2A6 P11509 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2B6 P20813 1/20 0.44
CYP2C19 P33261 1/20 0.44
P2RX7 Q99572 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25378454 1.00 ALDH1A1 (0.48) ALDH1A1KDM4ENPC1LMNAHPGD
SCHEMBL25828536 0.88 ALDH1A1 (0.44) ALDH1A1KDM4ENPC1LMNAHPGD
SCHEMBL26192334 0.87 MET (0.46) ALDH1A1KDM4ENPC1LMNAHPGD
SCHEMBL30561777 0.87 ALDH1A1 (0.44) ALDH1A1KDM4ENPC1LMNAHPGD
SCHEMBL25380685 0.87 ALDH1A1 (0.44) ALDH1A1KDM4ENPC1LMNAHPGD
SCHEMBL26192797 0.86 KDM4E (0.46) ALDH1A1KDM4ENPC1LMNAHPGD
SCHEMBL25379538 0.85 KDM4E (0.48) ALDH1A1KDM4ENPC1LMNAHPGD
SCHEMBL25257341 0.83 ALDH1A1 (0.43) ALDH1A1KDM4ENPC1LMNAHPGD
SCHEMBL30510019 0.83 ALDH1A1 (0.43) ALDH1A1KDM4ENPC1LMNAHPGD
SCHEMBL30561643 0.83 KDM4E (0.52) ALDH1A1KDM4ENPC1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12552772-B2 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD SPRINGWORKS THERAPEUTICS, INC. (US) 2026-02-17 US disclosed
US-20250115574-A1 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD VIB VZW (BE) 2025-04-10 US disclosed
EP-4452253-A2 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD The Katholieke Universiteit Leuven (BE) 2024-10-30 EP disclosed
US-12030866-B2 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD SPRINGWORKS THERAPEUTICS, INC. (US) 2024-07-09 US disclosed
WO-2023122780-A9 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD THE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed
US-20230278982-A1 2-Pyrazole Anilines and Related Analogs for Inhibiting YAP/TAZ-TEAD KU LEUVEN R&D (BE) 2023-09-07 US disclosed
WO-2023122780-A2 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD THE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12552772-B2 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD YAP1, TEAD3, TEAD2 ALDH1A1 1935/4885KDM4E 516/4885NPC1 1070/4885
US-20230278982-A1 2-Pyrazole Anilines and Related Analogs for Inhibiting YAP/TAZ-TEAD YAP1, TEAD3, TEAD2 ALDH1A1 2212/4885KDM4E 1163/4885NPC1 2100/4885
US-12030866-B2 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD YAP1, TEAD3, TEAD2 ALDH1A1 2212/4885KDM4E 1163/4885NPC1 2100/4885
US-20250115574-A1 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD YAP1, TEAD3, TEAD2 ALDH1A1 2212/4885KDM4E 1163/4885NPC1 2100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.